Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116875 - 116875
Опубликована: Март 1, 2025
Язык: Английский
Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116875 - 116875
Опубликована: Март 1, 2025
Язык: Английский
Translational Oncology, Год журнала: 2025, Номер 53, С. 102312 - 102312
Опубликована: Фев. 3, 2025
Язык: Английский
Процитировано
0International Journal of Biology and Life Sciences, Год журнала: 2025, Номер 9(2), С. 20 - 27
Опубликована: Фев. 26, 2025
Gastrointestinal stromal tumor (GIST) is a mesenchymal commonly found in the gastrointestinal tract and its pathogenesis mainly associated with c-KIT PDGFRA gene mutations. Surgery standard treatment for limited GIST, while imatinib (IM) first-line patients advanced or unresectable GIST. However, resistance (both primary secondary resistance) remains major challenge of To address this challenge, second-line drug sunitinib, third-line regorafenib, fourth-line Ripretinib, as well avapritinib targeting D842V mutation, have been introduced into clinic. In addition, therapeutic agents wild-type such SDH-deficient, NTRK-fusion BRAF V600E mutant, shown initial efficacy. Next-generation TKIs other strategies (e.g., heat shock protein inhibitors, mTOR immunotherapy) are still being explored, bringing new hope to drug-resistant future, in-depth study mechanisms, development personalized regimens, exploration combination therapies will hopefully further improve survival quality life GIST patients.
Язык: Английский
Процитировано
0iScience, Год журнала: 2025, Номер 28(4), С. 112183 - 112183
Опубликована: Март 12, 2025
Renal cell carcinoma (RCC), particularly clear RCC (ccRCC), has seen rising incidence and mortality rates. Early detection remains difficult due to nonspecific symptoms, often leading diagnoses at advanced stages unfavorable prognoses. Current treatments, including surgery, targeted therapies, immunotherapies, face limitations such as adverse reactions, drug resistance, immune evasion. This review discusses the role of circular RNAs (circRNAs) their involvement in circRNA/miRNA/mRNA axis during progression. As competitive endogenous (ceRNAs), circRNAs regulate gene expression cellular processes, proliferation, metastasis, apoptosis, resistance. Furthermore, we explore impact on tumor metabolic reprogramming influence microenvironment. We also summarize clinical prospects, challenges, future directions this field. A comprehensive understanding these complex interactions may provide new insights into diagnosis treatment RCC, ultimately overcoming existing challenges improving patient outcomes.
Язык: Английский
Процитировано
0Cellular Signalling, Год журнала: 2025, Номер unknown, С. 111744 - 111744
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116875 - 116875
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0